In a recent issue of the New England Journal of Medicine, Cho et al. () provided an interesting and very comprehensive description of an alcohol-dependent patient affected by alcoholic liver disease with fibrosis, brain abscess due to toxoplasma, and advanced HIV infection. This case report is a good reminder of three important clinical issues, i.e. (a) HIV-infected alcoholic patients drink more than the general population, alcohol is their most commonly abused drug and contributes to HIV-related morbidity, mortality, and transmission (Fenton et al., ); (b) HIV-infected alcoholic patients often have hepatic impairment because of alcohol's effects on liver, HCV coinfection, and antiretroviral therapy (ART)-related hepatotoxicity risk (Szabo and Zakhari, ); indeed, alcohol alone, like in this patient (Cho et al., ), can be harmful enough to develop clinically significant ALD – notably, in this patient ALD delayed ART initiation (Cho et al., ), which may have contributed to further clinical deterioration; (c) Alcohol interventions are dramatically needed for HIV-infected patients. This patient had declined treatment, e.g., disulfiram (Cho et al., ), a drug that itself might cause liver failure (Edwards et al., ). Though preliminary research is searching for safer and more effective pharmacotherapies (e.g., Addolorato et al., ; Johnson et al., ; Leggio et al., , ), this case (Cho et al., ) highlights the need to identify novel pharmacotherapies for alcoholic patients with ALD in order to provide effective interventions that both promote abstinence and help prevent progression to hepatic failure and death.
References
1
AddoloratoG.LeggioL.FerrulliA.CardoneS.VonghiaL.MirijelloA.AbenavoliL.D'AngeloC.CaputoF.ZambonA.HaberP. S.GasbarriniG. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet370, 1915–1922.10.1016/S0140-6736(07)61814-5
2
ChoT. A.LarvieM.TianD.Mino-KenudsonM. (2012). Case records of the Massachusetts General Hospital. Case 6-2012. A 45-year-old man with a history of alcohol abuse and rapid cognitive decline. N. Engl. J. Med.366, 745–755.10.1056/NEJMcpc1103558
3
EdwardsS.KennaG. A.SwiftR. M.LeggioL. (2011). Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: a review. Curr. Pharm. Des.17, 1323–1332.10.2174/138161211796150765
4
FentonM.LeggioL.KennaG. A.SwiftR. M. (2010). HIV testing in hazardous drinking: a survey analysis. Subst. Use Misuse45, 204–212.10.3109/10826080902882839
5
JohnsonB. A.RosenthalN.CapeceJ. A.WiegandF.MaoL.BeyersK.McKayA.Ait-DaoudN.AddoloratoG.AntonR. F.CirauloD. A.KranzlerH. R.MannK.O'MalleyS. S.SwiftR. M.Topiramate for Alcoholism Advisory Board, and Topiramate for Alcoholism Study Group. (2008). Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch. Intern. Med.168, 1188–1199.10.1001/archinte.168.11.1188
6
LeggioL.FerrulliA.ZambonA.CaputoF.KennaG. A.SwiftR. M.AddoloratoG. (2012). Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict. Behav.37, 561–564.10.1016/j.addbeh.2011.12.010
7
LeggioL.KennaG. A.FerrulliA.ZywiakW. H.CaputoF.SwiftR. M.AddoloratoG. (2011). Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum. Psychopharmacol.26, 554–559.10.1002/hup.1244
8
SzaboG.ZakhariS. (2011). Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients. World J. Gastroenterol.17, 2500–2506.10.3748/wjg.v17.i20.2500
Summary
Keywords
alcohol, alcoholic liver disease, alcoholism pharmacotherapy, HIV
Citation
Leggio L, Promrat K and Kenna GA (2012) A Call to Action: Alcohol Interventions in HIV-Infected Patients. Front. Psychiatry 3:35. doi: 10.3389/fpsyt.2012.00035
Received
28 March 2012
Accepted
28 March 2012
Published
17 April 2012
Volume
3 - 2012
Copyright
© 2012 Leggio, Promrat and Kenna.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
*Correspondence: lorenzo_leggio@brown.edu
This article was submitted to Frontiers in Addictive Disorders, a specialty of Frontiers in Psychiatry.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.